lystn

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/glp-1-ra-a-powerful-tool-for-risk-reduction-in-diabetes

Featuring speaker Javier Morales, MD, FACP, FACE, moderated by Gregg Sherman, MD.

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of therapies used for the treatment of patients with type 2 diabetes (T2D). However, the role of GLP-1 RA therapy continues to evolve and expands beyond glycemic control for these patients, and includes cardiorenal protective effects. Recently updated clinical practice guidelines now recommend treatment with GLP-1 RA therapy that has demonstrated benefit in cardiovascular risk reduction in all patients with T2D.

In this podcast episode, Dr. Javier Morales and Dr. Gregg Sherman discuss strategies for selecting optimal GLP-1 RA, the early initiation of GLP-1 RA therapy in appropriate patients, and improved adherence through adverse event management.

This podcast was recorded and is being used with the permission of the presenters.

Learning Objective

Upon completion of this activity, learners should be able to:

• Select GLP-1 RA therapy for early use in appropriate patients with T2DM, based on current guidelines, patient characteristics, and evolving data 
• Incorporate management strategies for the adverse gastrointestinal effects of GLP-1 RAs to improve patient adherence

This activity is accredited for CME/CE Credit.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/glp-1-ra-a-powerful-tool-for-risk-reduction-in-diabetes

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).

This educational activity is supported by an independent educational grant from Novo Nordisk Inc.